Tagged with B

Brunel Warren Shapiro, manager of the North American division of Brunel’s life science sector, offers his insights into Canada’s immense human resources capabilities as well as Brunel’s footprint for contract labor in Canada’s life sciences industry in comparison to other worldwide regions. You have covered jurisdictions in Canada, US and Latin…

Biosimilars Jaw-Jou Kang, former Director General of Taiwan Food & Drug Administration (TFDA) discusses the key successes the company has had since 2010, where it is looking to in the future and how a relationship with China would be mutually beneficial for both countries. Since Taiwan Food & Drug Administration’s founding…

Bioscience The CEO of OBIO discusses Ontario’s challenges and opportunities in life sciences, highlighting some of the key initiatives that the organization is taking to help local companies bridge the gap between research and commercialization. What was your main objective in founding OBIO back in 2009? The main motivation for founding…

Biosimilars Jim Keon, Preisdent of CGPA, discusses the cost-saving benefits that generic drugs have offered Canada, and offers his insights into Canada’s intellectual property regime and the challenges of pricing in Canada. As a privileged witness to the evolution of the Canadian generic industry, what have been some of the defining…

Ernst & Young LLP   Mario Piccinin and Lara Iob of EY Canada discuss some of the key trends of the country’s biotech industry and the affiliate’s dedication to helping clients navigate the SR&ED tax credit process available in Canada.   What do you see as the biggest challenges of life sciences clients in…

Agro-Food President of Biotalent Canada discusses the advantages of being wholly aligned with the government, why the BioTalent is a necessary link between talent and company, and what this means for the bio-economy of Canada. What was your initial mission two years ago upon arriving at Biotalent Canada, having previously worked…

investment The Deputy Executive Secretary of Taiwan’s National Development Fund discusses the recent shift in focus from semiconductors to biotech investments; why this has been a huge success thus far and why international collaboration will further benefit the market in Taiwan. Over the years, the National Development Fund (NDF) has increasingly…

Financial Management YFY Biotech Management Company has not always been involved in the biotech sector. How has it evolved over the years? Yuen Foong Yu Group originally began as a paper mill company, which grew alongside Taiwan as the country moved from agriculture to industry. In moving away from its traditional business…

Generics Dr. Chen, you joined US-based Anchen Pharmaceuticals in 2009 to help the company form a spin-off in Taiwan. Why did a US-based company look to establish itself in Taiwan, and then export back to the US? In my view, the US is not a very attractive environment for a company…

Biopharmaceuticals Over the past decade since its founding, what are some of the highlights in the transformation of Taiwan Advance Bio-Pharmaceutical Inc. (TABP) into a well established company? TABP was founded in 2000 as a spinoff of the Development Center for Biotechnology (DCB). The DCB was established in 1984 to support…

GCB Mr. Lin, you enjoyed a decades-long career in the ICT industry before making the transition to healthcare. What can you tell our readers about the evolution of General Biologics Corp. under your leadership? GBC was established in 1984. Government shareholders held 70 percent ownership, with the remaining 30 percent distributed…

API Industry Formosa Laboratories is one of Taiwan’s international pioneers in small molecules, entering the global arena at a very early stage. How did that decision come about? Generally speaking, Taiwan’s API industry decided to go global long before the formulation sector did. The reason is simple: the local market for APIs…